The Living Guidelines: Pharmacological enhancement of direct-current cardioversion: Polling Results for CLASS IIb Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIb Guidelines
1. For patients with persistent AF, administration of beta blockers, disopyramide, diltiazem, dofetilide, procainamide, or verapamil may be considered, although the efficacy of these agents to enhance the success of direct-current cardioversion or to prevent early recurrence of AF is uncertain. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 1 for pharmacological enhancement of direct-current cardioversion should be: CLASS I CLASS IIa CLASS IIb CLASS III 2. Out-of-hospital initiation of antiarrhythmic medications may be considered in patients without heart disease to enhance the success of cardioversion of AF. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 2 for pharmacological enhancement of direct-current cardioversion should be: CLASS I CLASS IIa CLASS IIb CLASS III 3. Out-of-hospital administration of antiarrhythmic medications may be considered to enhance the success of cardioversion of AF in patients with certain forms of heart disease once the safety of the drug has been verified for the patient. (Level of Evidence: C)

 ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 3 for pharmacological enhancement of direct-current cardioversion should be: CLASS I CLASS IIa CLASS IIb CLASS III